Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin

Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. Despite aggressive therapy, survival outcomes remain unsatisfactory, especially for patients with metastatic disease or patients with a poor chemotherapy response. Chemoresistance contributes to treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: De Boer, Jantine Posthuma, van Egmond, Pim W., Helder, Marco N., de Menezes, Renée X., Cleton-Jansen, Anne-Marie, Beliën, Jeroen A.M., Verheul, Henk M. W., van Royen, Barend J., Kaspers, Gert-Jan J.L., van Beusechem, Victor W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717953/
https://www.ncbi.nlm.nih.gov/pubmed/23045411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717953/
https://www.ncbi.nlm.nih.gov/pubmed/23045411

Ejemplares similares